↑ 薬物リストへ　← 戻る

Clobazam    (DrugBank: Clobazam)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
140ドラベ症候群5
144レノックス・ガストー症候群7

140. ドラベ症候群　［臨床試験数：83，薬物数：54（DrugBank：13），標的遺伝子数：48，標的パスウェイ数：62］
Searched query = "Dorabe syndrome", "Dravet syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 83 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02174094
(ClinicalTrials.gov)		March 20152/6/2014Clobazam as Adjunctive Therapy in Paediatric Patients Aged =1 to =16 Years With Dravet SyndromeMulti-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged =1 to =16 Years With Dravet SyndromeDravet SyndromeDrug: Clobazam;Drug: PlaceboH. Lundbeck A/SNULLWithdrawn1 Year16 YearsBoth0Phase 3United States;Mexico
2NCT02187809
(ClinicalTrials.gov)		March 20159/7/2014Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged =1 to =16 Years With Dravet SyndromeMulti-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged =1 to =16 Years With Dravet SyndromeDravet SyndromeDrug: ClobazamH. Lundbeck A/SNULLTerminated1 Year16 YearsAll3Phase 3United States;Mexico
3EUCTR2007-001784-30-FR
(EUCTR)		19/07/200701/06/2007Population pharmacokinetic study in Dravet's syndrome patients treated with stiripentol, valproate and clobazam. Open pharmacokinetic multicenter study.Population pharmacokinetic study in Dravet's syndrome patients treated with stiripentol, valproate and clobazam. Open pharmacokinetic multicenter study. AntiepilepticTrade Name: DIACOMIT
Product Name: DIACOMIT
Trade Name: DIACOMIT
Product Name: DIACOMIT		BIOCODEXNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		France
4EUCTR2007-003702-95-IT
(EUCTR)		03/07/200707/09/2007A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET'S SYNDROME (SMEI) NOT ADEQUATELY CONTROLLED WITH CLOBAZAM AND VALPROATE, AND AUXILIARY PHARMACOGENETIC STUDY - NDA MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET'S SYNDROME (SMEI) NOT ADEQUATELY CONTROLLED WITH CLOBAZAM AND VALPROATE, AND AUXILIARY PHARMACOGENETIC STUDY - ND Dravet Syndrome
Level: PTClassification code 10054859		Trade Name: stiripentolo
Trade Name: TOPAMAX
INN or Proposed INN: Topiramate
Trade Name: FRISIUM*30CPS 10MG
INN or Proposed INN: Clobazam		ISTITUTO C. MONDINONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		90Italy
5EUCTR2007-002198-30-IT
(EUCTR)		03/07/200717/01/2012A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET`S SYNDROME (SMEI), AND AUXILIARY PHARMACOGENETIC STUDYA MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET`S SYNDROME (SMEI), AND AUXILIARY PHARMACOGENETIC STUDY Dravet Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10054859;Term: Myoclonic epilepsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: stiripentolo
INN or Proposed INN: Other antiepileptics
Trade Name: TOPAMAX
INN or Proposed INN: Topiramate
Trade Name: FRISIUM*30CPS 10MG
INN or Proposed INN: Clobazam		Inserm-ISP Pole Recherches cliniques et thérapeutiquesNULLNot RecruitingFemale: yes
Male: yes		90Italy

先頭へ


144. レノックス・ガストー症候群　［臨床試験数：80，薬物数：63（DrugBank：11），標的遺伝子数：49，標的パスウェイ数：59］
Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 80 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-004350-82-BG
(EUCTR)		10/11/200813/11/2008Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome - Lennox-Gastaut syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome		Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 5mg
INN or Proposed INN: CLOBAZAM
Other descriptive name: Clobazam PhEur
Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 10mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam PhEur
Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 20mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam Pheur		Ovation PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes		304Bulgaria;Lithuania
2EUCTR2007-004322-24-BG
(EUCTR)		28/10/200803/11/2008Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. Lennox-Gastaut Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome		Trade Name: Clobazam
Product Name: Clobazam Tablets 5mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam PhEur		Ovation Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes		240Bulgaria;Lithuania
3EUCTR2007-004322-24-LT
(EUCTR)		17/03/200821/01/2008Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. Lennox-Gastaut Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome		Trade Name: Clobazam
Product Name: Clobazam Tablets 5mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam PhEur		Lundbeck IncNULLNot RecruitingFemale: yes
Male: yes		240Bulgaria;Lithuania
4EUCTR2007-004350-82-LT
(EUCTR)		17/03/200821/01/2008Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome - Lennox-Gastaut syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome		Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 5mg
INN or Proposed INN: CLOBAZAM
Other descriptive name: Clobazam PhEur
Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 10mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam PhEur
Trade Name: Clobazam
Product Name: Clobazam Tablets
Product Code: Clobazam Tablets 20mg
INN or Proposed INN: Clobazam
Other descriptive name: Clobazam Pheur		Lundbeck IncNULLNot RecruitingFemale: yes
Male: yes		304Bulgaria;Lithuania
5NCT00518713
(ClinicalTrials.gov)		August 200720/8/2007Clobazam in Patients With Lennox-Gastaut SyndromeDouble-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut SyndromeEpilepsy;Epilepsy, Generalized;SeizuresDrug: Clobazam Low Dose;Drug: Clobazam Medium Dose;Drug: Clobazam High Dose;Drug: PlaceboLundbeck LLCNULLCompleted2 Years60 YearsAll238Phase 3United States;Australia;Belarus;India;Lithuania;Serbia
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT01160770
(ClinicalTrials.gov)		December 200518/6/2010Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut SyndromeSafety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut SyndromeLennox-Gastaut SyndromeDrug: ClobazamLundbeck LLCNULLCompleted2 Years60 YearsAll267Phase 3NULL
7NCT00162981
(ClinicalTrials.gov)		October 20059/9/2005Clobazam in Subjects With Lennox-Gastaut SyndromeSafety and Efficacy of Clobazam in Subjects With Lennox-Gastaut SyndromeEpilepsy;Epilepsy, Generalized;SeizuresDrug: Clobazam Low Dose;Drug: Clobazam High DoseLundbeck LLCNULLCompleted2 Years30 YearsAll68Phase 2United States

先頭へ